ProCE Banner Activity

Venetoclax Monotherapy in R/R CLL With del(17p)

Slideset Download
Conference Coverage
Single-agent venetoclax is active and achieved deep responses in relapsed/refractory CLL with del(17p).

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen